Ask about this productRelated genes to: DMRTC2 antibody
- Gene:
- DMRTC2 NIH gene
- Name:
- DMRT like family C2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-11-24
- Date modifiied:
- 2016-01-19
Related products to: DMRTC2 antibody
Related articles to: DMRTC2 antibody
- Total RNA was isolated from sections of healthy testes and Leydig cell tumors of mixed-breed dogs using TMA Master II device. The RNA-seq libraries were sequenced on the Illumina platform. Following differential expression analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were applied with quality control obtained using FastQC and Trimmomatic. This analysis revealed 1500 transcripts, including 982 upregulated and 168 downregulated genes. The results demonstrated that a significant proportion of these differentially expressed genes are directly involved in the control of sex steroid production (, , and ) or tube formation, angiogenesis, and extracellular matrix remodeling in interstitial cells (, , and ). Moreover, we identified the upregulation of transcripts responsible for neurotransmitter or neuroendocrine signaling (, , ) and cholesterol metabolism and its regulation (, , ). These genes were strongly associated with the phosphatidylinositol-3-kinase (PI3K)-Protein Kinase B (Akt) cascade and extracellular matrix interactions, features shared with various malignancies. Alterations in estrogen and relaxin signaling appear to be distinctive, understudied mechanisms specific to canine Leydig cell tumors. Concurrently, downregulated genes (e.g., , , ) were linked with cell differentiation, signaling and immunoregulatory pathway suppression involved in tumorigenesis. A complex transcriptomic profile of canine Leydig cell tumors was developed, revealing a conserved oncogenic core shared in some aspects with human malignancies alongside unique species-specific alterations. Findings seem to be useful for identifying novel diagnostic biomarkers and targeted therapies in veterinary oncology, establishing canine reproductive tissues as a valuable comparative biomedical model for research in human. - Source: PubMed
Publication date: 2026/07/01
Kotula-Balak MalgorzataUyar RecepMorańska EmiliaLonc GrzegorzBoztepe Ummu GulsumLopuszynski Wojciech - Human germline gene expression is normally constrained to the germ cells, responsible for the production of sperm and oocytes. Cancer-germline (CG) genes, a subset of germline genes involved in testis development, are frequently aberrantly activated in cancer cells. The present study investigates the broader hypothesis that epigenetic modifications, specifically DNA methylation, can modulate the expression profiles of several CG genes in cancer and germ cells. Breast cancer (BC), normal breast (NB), and chronic myelogenous leukemia (CML) cell lines were treated with the DNA methyltransferase inhibitor (DNMTi) 5-aza-2'-deoxycytidine for three days. The effects of this treatment on the transcriptional activation of CG genes (SYCP1, ADAD1, SYCE1, PRSS54, DMRTC2, and TEX101) were then evaluated. We comprehensively analyzed differential methylation, survival analysis (Kaplan-Meier), correlation (Spearman's), and pathway enrichment analysis (GO/KEGG) of CG genes (SYCP1, ADAD1, SYCE1, PRSS54, DMRTC2, and TEX101) in BC and leukemia. Treatment with 5-aza-2'-deoxycytidine upregulated CG genes in BC cells but downregulated them in leukemia cells, highlighting tissue-specific epigenetic responses. Differential methylation analysis revealed cancer-specific patterns: ADAD1 was hypermethylated in both malignancies, while PRSS54 was hypomethylated in leukemia. Survival analysis linked SYCE1 and PRSS54 to prolonged survival in BC, whereas TEX101 and SYCP1 correlated with poorer outcomes. Functional enrichment identified ADAD1 and SYCP1 as key players in BC and leukemia pathways, respectively. Meta-analysis validated SYCP1 as a robust biomarker with consistent effect sizes across datasets. Methylation-expression correlations were stronger in tumors, with SYCE1 and DMRTC2 showing inverse relationships in leukemia. These findings demonstrate that the expression of a subset of CG genes is responsive to modulation by hypomethylating drugs in a tissue-specific manner, highlighting their promise as candidates for future investigation in cancer immunotherapy. - Source: PubMed
Publication date: 2025/12/18
Almutairi Mikhlid HAlrubie Turki M - - Source: PubMed
Publication date: 2025/11/11
Gan Xian-YouMeng YueLing Xiao-BinRan Lan-XiYang ManLi Teng-YanSun YanWang Bin-Bin - Colon cancer (CC) is a significant cause of death worldwide, particularly in Saudi Arabia. To increase the accuracy of diagnosis and treatment, it is important to discover new specific biomarkers for CC. The main objectives of this research are to identify potential specific biomarkers for the early diagnosis of CC by analyzing the expressions of eight cancer testis (CT) genes, as well as to analyze how epigenetic mechanisms control the expression of these genes in CC cell lines. Tissue samples were collected from 15 male patients with CC tissues and matched NC tissues for gene expression analysis. The expression levels of specific CT genes, including ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12, were assessed using quantitative techniques. To validate the gene expression patterns, we used publicly available CC statistics. To investigate the effect of inhibition of DNA methylation and histone deacetylation on CT gene expression, in vitro experiments were performed using HCT116 and Caco-2 cell lines. There was no detected expression of the genes neither in the patient samples nor in NC tissues, except for TEX48, which exhibited upregulation in CC samples compared to NC tissues in online datasets. Notably, CT genes showed expression in testis samples. In vitro, experiments demonstrated significant enhancement in mRNA expression levels of ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12 following treatment with 5-aza-2'-deoxycytidine and trichostatin A in HCT116 and Caco-2 cell lines. Epigenetic treatments modify the expression of CT genes, indicating that these genes can potentially be used as biomarkers for CC. The importance of conducting further research to understand and target epigenetic mechanisms to improve CC treatment cannot be overemphasized. - Source: PubMed
Publication date: 2024/08/29
Almutairi Mikhlid HAlrubie Turki MAlshareeda Alaa TAlbarakati NadaAlmotiri AlhomidiAlamri Abdullah MAlmutairi Bader OAlanazi Mohammad - The acid β-glucocerebrosidase (GCase) enzyme cleaves glucosylceramide into glucose and ceramide. Loss of function variants in the gene encoding for GCase can lead to Gaucher disease and Parkinson's disease. Therapeutic strategies aimed at increasing GCase activity by targeting a modulating factor are attractive and poorly explored. To identify genetic modifiers, we measured hepatic GCase activity in 27 inbred mouse strains. A genome-wide association study (GWAS) using GCase activity as a trait identified several candidate modifier genes, including and (p=2.1x10), and (p=2.1x10). Bayesian integration of the gene mapping with transcriptomics was used to build integrative networks. The analysis uncovered additional candidate GCase regulators, highlighting modules of the acute phase response (p=1.01x10), acute inflammatory response (p=1.01x10), fatty acid beta-oxidation (p=7.43x10), among others. Our study revealed previously unknown candidate modulators of GCase activity, which may facilitate the design of therapies for diseases with GCase dysfunction. - Source: PubMed
Publication date: 2021/08/18
Durán AnyeloRebolledo-Jaramillo BorisOlguin ValeriaRojas-Herrera MarceloLas Heras MacarenaCalderón Juan FZanlungo SilvanaPriestman David APlatt Frances MKlein Andrés D